Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Levy who wrote (756)	8/24/1999 8:11:00 AM
From: Just4Fun	Respond to of 900

August 24, 1999 07:15 The Liposome Company Receives Regulatory Approval for Abelcet(R) in Belgium PRINCETON, N.J., Aug. 24 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that it has received regulatory approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) from the Ministry of Health in Belgium. The indication for ABELCET(R) is for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. ABELCET(R), a complex of amphotericin B with two phospholipids, is developed and manufactured by The Liposome Company as a treatment for severe, systemic fungal infections such as aspergillosis, candidiasis and cryptococcal meningitis. The fungi that cause these infections are easily destroyed by an individual's healthy immune system. However, patients whose immune systems have been compromised, often as a result of chemotherapy for cancer, treatment for bone marrow or solid organ transplantation, or AIDS may be unable to stave off these infectious organisms. Amphotericin B has been the standard therapy for such infections for many years. Its use is limited, however, by its potential to cause kidney toxicity. ABELCET(R)'s unique lipid complex design allows it to retain the antifungal activity of amphotericin B while alleviating much of the toxicity affecting the kidneys, even when delivered at much higher doses. The Liposome Company is a biopharmaceutical company developing, manufacturing and marketing therapeutic products to treat cancer and related diseases. ABELCET(R) (Amphotericin B Lipid Complex Injection) which has now been approved in 23 countries, is marketed in the United States for the treatment of severe, systemic fungal infections in patients who are refractory to or intolerant of conventional therapy and is the leading lipid-based formulation of amphotericin B in this country. Preparations are underway to file a New Drug Application in the U.S. for the Company's second drug, EVACET(TM) (formerly TLC D-99) liposomal doxorubicin, to treat metastatic breast cancer. The Company's product pipeline includes TLC ELL-12 and bromotaxol for the treatment of various cancers and programs focused on the development of new cancer therapies and vehicles for the delivery of gene therapy.